09.11.2014 Views

CRF Design & Utilization - UKM Medical Centre

CRF Design & Utilization - UKM Medical Centre

CRF Design & Utilization - UKM Medical Centre

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

GCP Course<br />

Pusat Perubatan <strong>UKM</strong><br />

Kuala Lumpur<br />

T Mahendran<br />

Consultant, <strong>Medical</strong> Affairs<br />

SS Inter Pharma Consultants<br />

Kuala Lumpur, Malaysia<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 1


ICH GCP<br />

• 8 Sections covering the<br />

• principal participants<br />

and responsibilities<br />

• ethics committees<br />

• investigator<br />

• sponsor incl. monitor<br />

• principal procedures<br />

• designing<br />

• conducting<br />

• recording<br />

• reporting<br />

of clinical<br />

studies<br />

• main paperwork<br />

• main terms<br />

• clinical study protocol<br />

• investigator’s brochure<br />

• clinical study report<br />

• essential documents<br />

glossary including 62 terms from<br />

adverse drug reaction to wellbeing<br />

of trial subjects<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 2


Case Report Forms (<strong>CRF</strong>) <strong>Design</strong><br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 3


What‟s A <strong>CRF</strong>?<br />

A Case Report Form (or <strong>CRF</strong>) is the tool<br />

used to collect data; it can be a paper- or<br />

electronic-based questionnaire specifically<br />

used in a clinical trial/research.<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 4


Purpose of the <strong>CRF</strong><br />

• Collection of relevant data in a specific format<br />

• As per protocol<br />

• In compliance with all regulatory requirements<br />

• Allows for efficient and complete data processing,<br />

analysis and reporting<br />

• Facilitates the exchange of data across projects and<br />

organizations esp. through standardization<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong>


Relationship of <strong>CRF</strong> to Protocol<br />

• Protocol determines what data should<br />

be collected in the <strong>CRF</strong><br />

• All data specified in the protocol must<br />

be collected in the <strong>CRF</strong><br />

• Data that will not be analyzed should<br />

not appear in the <strong>CRF</strong><br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong>


<strong>CRF</strong> <strong>Design</strong> & Development Process<br />

Involvement of all Stakeholders<br />

• Project Clinician/<strong>Medical</strong> Director<br />

• Clinical Research Associate (CRA)<br />

• Statistician<br />

• Database Programmer<br />

• Data Manager<br />

• Others<br />

• Standards, Dictionary Coding,<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong>


Poorly <strong>Design</strong>ed <strong>CRF</strong>s<br />

• Garbage In = Garbage Out<br />

• Data not collected<br />

• Database may require modification<br />

• Need to edit data<br />

• Target dates are missed<br />

• Over-collection of (irrelevant) data –<br />

resources wasted in collecting & processing<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong>


<strong>CRF</strong> <strong>Design</strong> Overview<br />

in Industry<br />

• Harmonization of recording patient data<br />

• Process of creating <strong>CRF</strong>s<br />

• <strong>CRF</strong> layout<br />

• General structure<br />

• Individual modules (building blocks of <strong>CRF</strong>)<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 9


Harmonized <strong>CRF</strong> Modules<br />

acc. to Sponsor Standards<br />

Standard Templates exist for the following <strong>CRF</strong> Modules:<br />

• Informed Consent (incl. Contraception/Pregnancy)<br />

• Demographic Data<br />

• Physical Examination<br />

• Vital Signs/ECG<br />

• <strong>Medical</strong> History<br />

• Laboratory/Urinalysis<br />

• Adverse Events<br />

• Concomitant Medication<br />

• Study Medication<br />

• Termination Section<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 10


<strong>CRF</strong> <strong>Design</strong><br />

• Harmonization (bringing in agreement) of<br />

individual components of <strong>CRF</strong><br />

= agreement on systematic way of asking<br />

for patient data<br />

• Use of standard templates and modules<br />

• <strong>Design</strong>-Tool: QuarkXPress (a professional<br />

layout all program)<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 11


Path from<br />

study<br />

information<br />

(protocol) to<br />

printed <strong>CRF</strong><br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 12


Protocol<br />

<strong>CRF</strong>-<strong>Design</strong><br />

5 days<br />

<strong>CRF</strong> <strong>Design</strong> & Review<br />

Timelines<br />

<strong>CRF</strong>-<strong>Design</strong> +<br />

Data Management<br />

5 days<br />

Delivery<br />

1st Draft *<br />

Final<br />

Working<br />

Draft *<br />

Final<br />

Draft for<br />

Proof<br />

Printing<br />

Proof<br />

Print<br />

Final<br />

Print<br />

<strong>CRF</strong> Development<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 13


Overview<br />

Cover and Spine<br />

(Pantoprazole)<br />

cover and spine<br />

layout version of<br />

licenced product<br />

- phase IV study<br />

Confidentiality<br />

Barcode<br />

on all NCR pages for<br />

scanning of pages<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 14


Layout of <strong>CRF</strong>-Pages<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 15


Study Schedule/<br />

Overview<br />

‣ Time-saving quick<br />

reference<br />

‣ Outlines all study<br />

specific procedures<br />

‣ Indicates what to be<br />

done at which visit<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 16


Order of Sections<br />

General Structure of <strong>CRF</strong>s<br />

Visits (e.g. B0 – T12, V0 – V4)<br />

<strong>Medical</strong> History<br />

Planned Surgeries<br />

Adverse Events<br />

Concomitant Medication<br />

Study Medication<br />

Termination Section<br />

Serious Adverse Event Reporting Form<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 17


<strong>CRF</strong> Contents<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 18


Informed Consent / In-/Exclusion Criteria<br />

First of all....<br />

Patient IC<br />

Inclusion<br />

criteria<br />

Exclusion<br />

criteria<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 19


Demographic Data<br />

• Date of birth<br />

• Gender<br />

• Height<br />

• Weight<br />

• Race Asian<br />

Black<br />

White<br />

Other<br />

• Smoking<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 20


Physical Examination<br />

(Initial Visit / Termination Visit)<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 21


Changes in Medication / AE<br />

T4<br />

CM<br />

AE<br />

SM<br />

AE<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 22


<strong>Medical</strong> History<br />

• Study indication (e.g. asthma)<br />

preprinted, if applicable<br />

• Definition of "relevant previous"<br />

is study specific<br />

• Please check with section<br />

"Planned surgeries" because the<br />

underlying disease/diagnosis has<br />

to be entered here.<br />

• In case a diagnosis is deleted,<br />

please don't renumber.<br />

Reason: link to CM<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 23


Planned Surgeries / Invasive Procedures<br />

Enter name<br />

of planned<br />

surgery /<br />

procedure<br />

Enter actual<br />

date of event<br />

(or tick if not<br />

performed)<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 24


Adverse Events<br />

• Do not change the number of the AE<br />

• Please enter one diagnosis. If no<br />

diagnosis is available but only<br />

symptoms, for each symptom a<br />

separate AE form has to be filled in<br />

(e.g. nausea and vomiting)<br />

Reason: only one symptom can be<br />

coded.<br />

• Final outcome "unknown", please<br />

check, when collecting the <strong>CRF</strong>s<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

• Don't forget the mandatory comment<br />

on causality assessment.<br />

29/11/2011 25


Relevant Previous and Concomitant Medication<br />

MH<br />

AE<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 26


Study Medication<br />

• Study specific form<br />

• Mandatory:<br />

- Study medication (preprinted)<br />

- Start date<br />

- Stop date<br />

• Optional:<br />

- Study Period<br />

- Recording of returned medication<br />

- Dosage (frequency, strength)<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 27


Section T<br />

Extended by central<br />

safety tests (Laboratory<br />

test, ECG etc.)<br />

Premature discontinuation:<br />

Mandatory and optional reasons<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 28


Case Report Form (<strong>CRF</strong>) <strong>Utilization</strong><br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 29


ICH GCP<br />

• 8 Sections covering the<br />

• principal participants<br />

and responsibilities<br />

• ethics committees<br />

• investigator<br />

• sponsor incl. monitor<br />

• principal procedures<br />

• designing<br />

• conducting<br />

• recording<br />

• reporting<br />

of clinical<br />

studies<br />

• main paperwork<br />

• main terms<br />

• clinical study protocol<br />

• investigator’s brochure<br />

• clinical study report<br />

• essential documents<br />

glossary including 62 terms from<br />

adverse drug reaction to wellbeing<br />

of trial subjects<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 30


General Completion Instructions<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 31


Baseline visit B0<br />

• Informed<br />

consent<br />

has to be<br />

available<br />

• Inclusion/<br />

exclusion<br />

criteria<br />

check<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 32


Baseline visit B0<br />

No initials will be<br />

recorded in the<br />

<strong>CRF</strong> !<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 33


Baseline visit B0<br />

No entry<br />

necessary if<br />

„Others‟ is<br />

without findings<br />

No ECG entry!<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 34


Baseline visit B0<br />

Enter “Not Known”<br />

(NK) if data not<br />

available<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 35


Baseline visit B0 (B1 – B4)<br />

Within 1.5 h vs.<br />

anticipated time of T0<br />

Multiply predicted value acc.<br />

to Quanjer table with factor<br />

0.9 (if patient is non-european<br />

or non-caucasian)<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 36


Baseline visit B1<br />

verification of<br />

B0 lab results,<br />

if applicable<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 37


Baseline visit B1 (B2, B3, B4)<br />

x<br />

x<br />

Randomization<br />

criteria fulfilled<br />

=> go to T0<br />

x<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 38


Treatment visit T0<br />

Baseline period >2 weeks:<br />

Laboratory test<br />

Urinalysis<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 39


<strong>Medical</strong> history<br />

Diagnoses/<br />

diseases in the<br />

last 6 months<br />

prior to B0<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 40


Adverse events<br />

„yes‟ or „no‟<br />

to be ticked<br />

Final outcome<br />

to be entered<br />

also for FU<br />

Causality assessment<br />

should be given in any case!<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 41


Concomitant Medication<br />

Combination<br />

drugs – only trade<br />

names!<br />

Formulations as<br />

exact as possible<br />

Rescue<br />

medication<br />

(salbutamol)<br />

to be recorded<br />

only once<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

Strength of smallest unit<br />

29/11/2011 42


Study termination/Discontinuation report<br />

includes:<br />

• Physical examination<br />

• Vital signs<br />

• ECG<br />

• Laboratory investigations (no urinalysis)<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 43


Study termination/Discontinuation report<br />

Please check protocol<br />

for discontinuation criteria<br />

(chapter 13.1)<br />

Sign & date after<br />

last study-related<br />

activity<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 44


Thank you for your attention!<br />

~~~ Questions ~~~<br />

T Mahendran/<strong>CRF</strong> <strong>Design</strong> & <strong>Utilization</strong><br />

29/11/2011 45

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!